

EPHMRA
ANATOMICAL CLASSIFICATION
GUIDELINES 2022

Section B

Changed Classes/Guidelines

Final Version

Date of issue: 17th December 2021

A10M	GLINIDE ANTIDIABETICS	I2009
A10M1	Glinide antidiabetics, plain Includes plain products containing repaglinide, nataglinide, mitiglinide, etc.	I2009
A10M3	Glinide and biguanide antidiabetic combinations Includes combinations of glinide antidiabetics with biguanides.	I2009
A10M9	Glinide antidiabetic combinations, other Includes combinations of glinide antidiabetics with other antidiabetics where there is no other appropriate class.	I2009
A10N	DPP-IV INHIBITOR ANTIDIABETICS	I2009
A10N1	DPP-IV inhibitor antidiabetics, plain Includes plain products containing denagliptin, saxagliptin, sitagliptin, vildagliptin, etc.	I2009
A10N3	DPP-IV inhibitor and biguanide antidiabetic combinations Includes combinations of DPP-IV inhibitors with biguanides.	I2009
A10N9	DPP-IV inhibitor antidiabetic combinations, other Includes combinations of DPP-IV inhibitors with other antidiabetics where there is no other appropriate class. Combinations of a DPP-IV with a glitazone and a biguanide are classified in A10N9. Combinations of a DPP-IV inhibitor with an SGLT2 inhibitor and a biguanide are classified in A10P9.	r2020
A10P	SGLT2 INHIBITOR ANTIDIABETICS	R2016
A10P1	SGLT2 inhibitor antidiabetics, plain Includes plain products containing SGLT2 inhibitors, eg canagliflozin, dapagliflozin, empagliflozin, etc. Products containing SGLT2 inhibitors for diabetes and also for heart failure and/or chronic kidney disease are classified here.	r2022
A10P3	SGLT2 inhibitor and biguanide antidiabetic combinations Includes combinations of SGLT2 inhibitors with biguanides.	I2016
A10P5	SGLT2 inhibitor and DPP-IV inhibitor antidiabetic combinations Includes combinations of SGLT2 inhibitors with DPP-IV inhibitors.	I2017

A10P9	<p>SGLT2 inhibitor antidiabetic combinations, other</p> <p>Includes combinations of SGLT2 inhibitors with other oral antidiabetics where there is no other appropriate class. Combinations of an SGLT2 inhibitor with a DPP-IV inhibitor and a biguanide are classified here.</p>	r2020
A10S	<p>GLP-1 AGONIST ANTIDIABETICS</p> <p>Includes glucagon-like peptide 1 receptor agonist antidiabetics, eg exenatide, liraglutide, lixisenatide. Combinations of GLP-1 agonist antidiabetics with human insulins or analogues are classified in A10C9.</p> <p>Products containing oral forms of GLP-1 agonists for diabetes are classified here.</p> <p>Products containing tirzepatide, a dual GIP and GLP-1 agonist, for diabetes are classified here.</p> <p>Products containing liraglutide for weight management only are classified in A8A.</p>	r2022
A10X	<p>OTHER DRUGS USED IN DIABETES</p>	R2010
A10X1	<p>Antidiabetic multitherapy combination products</p> <p>Includes combinations of antidiabetics with cardiovascular drugs where the aim is to treat both the diabetes and the cardiovascular condition. For example, rosiglitazone in combination with simvastatin. Also includes combinations of antidiabetics with anti-obesity drugs where the aim is to treat both the diabetes and the obesity. For example, metformin in combination with sibutramine.</p>	I2010
A10X9	<p>Other drugs used in diabetes</p> <p>Includes products used for the treatment of diabetes, as well as adjuvant therapy in the treatment and prevention of conditions associated with or developing from diabetes.</p> <p>Includes aldose reductase inhibitors (eg epalrestat, tolrestat), guar gum and glucose products specifically intended for the treatment of hypoglycaemic shock.</p> <p>Teas and other herbal extracts used as adjuvant therapy are classified here.</p>	I2010

B1X	OTHER ANTITHROMBOTIC AGENTS Includes danaparoid, dermatan sulphate, activated protein C (drotrecogin alpha, activated), fondaparinux, <i>Ligustrum lucidum</i> , pentosan polysulphate sodium, poloxalkol, protein C. Products containing caplacizumab for acquired thrombotic thrombocytopenic purpura are classified here.	r2022
------------	--	-------

B2D	BLOOD COAGULATION PRODUCTS	r2022
B2D1	Factor VIII, including substitutes Includes antihaemophilic globulin A, emcizumab, etc. Products containing von Willebrand factor only are classified in B2D9.	r2019
B2D2	Factors II, VII, IX and X Includes antihaemophilic globulin B and prothrombin complex.	
B2D3	Anti-inhibitor-coagulation complex Includes aPCC (activated prothrombin complex concentrate), activated FVII (FVIIa), and eptacog alfa.	R2003
B2D4	Factor XIII	
B2D5	Fibrinogen	
B2D6	Fresh frozen plasma and antihaemophilic plasma	
B2D7	Cohn-Fraction I	
B2D8	Platelet concentrates	
B2D9	Other blood fractions Includes products containing von Willebrand factor (single ingredient).	R2005
B2E	THROMBOPOIETIN AGONISTS Includes products containing thrombopoietin agonists, such as eltrombopag and romiplostim. Products containing oprelvekin for the prevention of severe thrombocytopenia are classified in B6X.	r2021
B2F	TISSUE SEALING PREPARATIONS Includes products imitating the physiological process of fibrin formation which are used for tissue sealing, haemostasis and support of wound healing. Products containing thrombin/collagen for the prevention of bleeding prior to implantation of ICDs/pacemakers are classified here.	r2016

D5	<p>NONSTEROIDAL PRODUCTS FOR INFLAMMATORY SKIN DISORDERS</p> <p>Includes products for psoriasis, hyperkeratosis, ichthyosis, eczema, dermatitis, seborrhoea. Psoralens are classified here when used for inflammatory conditions. Excluded from this class are combinations with antibacterials (D6A), antifungals (D1A) and products specifically indicated in acne (D10A). Sulphur baths which contain other substances besides sulphur and are not used for dermatological purposes, are classified in M2A.</p>	<u>r2019</u>
D5A	<p>TOPICAL ANTIPSORIASIS PRODUCTS</p> <p>Includes products containing substances such as tar, coal tar, ichthammol, dithranol, psoralens, salicylic acid for the treatment of psoriasis. These products may also be for other inflammatory skin conditions. Products containing corticosteroids in combination with coal tar or salicylic acid for psoriasis are classified here. These products may also be for other inflammatory skin conditions.</p> <p>Includes products consisting of coal tar or calcipotriol, alone or in combination, when indicated for psoriasis.</p>	r2019
D5B	<p>SYSTEMIC ANTIPSORIASIS PRODUCTS</p> <p>Includes products for the treatment of psoriasis. These products may also be for other inflammatory skin conditions. Products containing brodalumab, ixekizumab, secukinumab or ustekinumab and indicated for psoriasis and also other non-skin conditions, eg arthritis, are classified in L4C. Psoriatic arthritis is defined as a skin condition.</p> <p>Apremilast is classified here if only for psoriatic skin conditions. Products containing apremilast for multiple conditions are classified in L4X.</p>	r2022
D5X	<p>OTHER NONSTEROIDAL PRODUCTS FOR INFLAMMATORY SKIN DISORDERS</p> <p>Includes nonsteroidal products for inflammatory skin disorders which are not indicated for psoriasis. Specific topical immunomodulators for dermatitis are classified here.</p> <p>Products containing ingenol mebutate or diclofenac gel that are indicated for actinic keratosis are classified here. Products containing aminolaevulinic acid for actinic keratosis, basal cell carcinoma or Bowen syndrome are classified in L1X8. Products containing topical fluorouracil for actinic keratosis are classified in L1B.</p> <p>Products containing dupilumab for atopic dermatitis only are classified here. Products containing dupilumab for both atopic dermatitis and asthma are classified in L4C.</p>	r2019

G3X	<p>OTHER SEX HORMONES AND SIMILAR PRODUCTS</p> <p>Includes mammary extracts and other hormonal preparations for sexual disorders eg placenta extracts. Cyproterone acetate (tab 10mg) is classified here; higher doses (50 mg) and injectable forms are in L2B2 when used as cytostatics. Includes products containing tibolone.</p> <p>Products containing mifepristone are classified here if indicated as abortifacients alone, or with other indications, or in G3A6 if indicated for emergency contraception.</p> <p>Products containing ulipristal are classified here if indicated for uterine fibroids, or in G3A6 if indicated for emergency contraception.</p> <p>Products containing relugolix or elagolix in combination with oestrogens and progestogens for uterine fibroids are classified here. Products containing relugolix or elagolix (single ingredient) for uterine fibroids or endometriosis are classified in H1C3. Products containing relugolix for cancer are classified in L2B9.</p>	r2022
------------	---	-------

H	SYSTEMIC HORMONAL PREPARATIONS (EXCLUDING SEX HORMONES)	
H1	PITUITARY AND HYPOTHALAMIC HORMONES	R1995
H1A	ACTH ACTH and synthetic analogues.	
H1B	Out of use; can be reused.	
H1C	HYPOTHALAMIC HORMONES	R2003
H1C1	Gonadotrophin-releasing hormones Includes eg buserelin, deslorelin, gonadorelin, goserelin, nafarelin, leuprorelin, triptorelin, when not used as cytostatics. When these substances are used as cytostatics, they are classified in L2A3. Products containing gonadotrophin-releasing hormone analogues for cancer and also for other conditions, are classified in L2A3.	r2020
H1C2	Antigrowth hormones Products for acromegaly are classified here. Lanreotide, octreotide and somatostatin are classified here. Somatostatin, when used as a haemostyptic, is classified in B2G. Growth hormone antagonists, such as pegvisomant, are classified here.	r2020
H1C3	Antigonadotrophin-releasing hormones Cetrorelix and ganirelix are classified here. Products containing relugolix or elagolix (single ingredient) for uterine fibroids or endometriosis are classified here. Products containing relugolix or elagolix in combination with oestrogens and progestogens for uterine fibroids are classified in G3X. Products containing relugolix for cancer are classified in L2B9.	r2022

H4	OTHER HORMONES	
H4A	CALCITONINS This group includes all calcitonin products (pork, salmon, eel and synthetic).	
H4B	GLUCAGON	
H4C	GROWTH HORMONES Includes products for growth conditions and also for AIDS wasting conditions. Products containing anamorelin for cachexia are classified here. Products containing lonapegsomatropin are classified here.	r2022
H4D	ANTIDIURETIC HORMONES This group includes argipressin, desmopressin, lypressin, ornipressin, vasopressin.	
H4E	PARATHYROID HORMONES AND ANALOGUES Includes parathyroid hormone analogues, teriparatide.	I2008
H4F	ANTIPARATHYROID PRODUCTS Includes products containing eg cinacalcet, doxercalciferol, falecalcitriol, maxacalcitol, paricalcitol, when they are indicated for secondary hyperparathyroidism. Products containing vitamin D or its analogues with multiple indications are classified in A11C2.	r2014
H4V	Out of use; can be reused from 2011.	D2008
H4X	OTHER HORMONES AND PREPARATIONS WITH SIMILAR ACTIONS Products containing melatonin only and indicated for sleep rhythm disturbances are classified here. Prolonged-release melatonin indicated for primary insomnia is classified in N5B1. Products for insomnia that contain a sedative/hypnotic plus melatonin are classified in N5B in the appropriate subclass (N5B2, N5B4 or N5B5).	r2009

J4	ANTIMYCOBACTERIALS	R1993
J4A	ANTITUBERCULAR PRODUCTS	r2009
	Includes all specific tubercular preparations as well as streptomycin and dihydrostreptomycin. Other antibacterials such as viomycin and cycloserine which are indicated specifically for tuberculosis are included as well as rifampicin and rifamycin where they are used mostly as tuberculostatics. Where rifampicin and rifamycin are indicated for several conditions, then they are classified in J1M.	
	The definition of 'single ingredient' means that only one specific antitubercular drug is present in the product. For example, if a product contains an antitubercular substance and also pyridoxine, this is a single ingredient product and will be classified in J4A1.	
	Kits include various different tablets or forms with different ingredients. Fixed dose products contain the ingredients in one dosage form.	
J4A1	Antituberculars, single ingredient	I2000
J4A2	Antituberculars, kits, four or more ingredients	I2000
J4A3	Antituberculars, kits, three ingredients	I2000
J4A4	Antituberculars, kits, two ingredients	I2000
J4A5	Antituberculars, fixed dose, four or more ingredients	I2000
J4A6	Antituberculars, fixed dose, three ingredients	I2000
J4A7	Antituberculars, fixed dose, two ingredients	I2000
J4A9	Antituberculars, others	I2000
J4B	DRUGS FOR THE TREATMENT OF LEPROSY	r2022
	Includes preparations used for the treatment of leprosy (eg aldesulphone, clofazimine, dapsone). Products containing thalidomide for cancer are classified in L1K and for erythema nodosum leprosum (ENL) in L4X. Products for both cancer and ENL are classified in L1K.	

J5	ANTIVIRALS FOR SYSTEMIC USE	R2018
J5A	Out of use	D1998
J5B	ANTIVIRALS, OTHER	r2022
	Includes systemic antivirals for herpes, influenza, coronavirus, other viral respiratory conditions, etc. Excludes topical skin antivirals (D6D), topical ophthalmic antivirals (S1D), HIV antivirals (J5C), and hepatitis antivirals (J5D).	
J5B1	Out of use	D2018
J5B2	Out of use	
J5B3	Herpes antivirals	I2008
	Products used against herpes virus infections, including specific systemic forms of products for cytomegalovirus infections (including CMV retinitis), are classified here. Products in topical ophthalmic forms for CMV retinitis are classified in S1D.	
J5B4	Influenza antivirals	r2022
	Includes products indicated specifically for influenza. Products containing favipiravir for influenza only are classified here. Products containing favipiravir for COVID-19 only are classified in J5B6. Products containing favipiravir for both influenza and COVID-19 are classified in J5B6.	
J5B5	Respiratory antivirals, other	R2022
	Includes products indicated specifically for treatment of respiratory syncytial virus (RSV) infections. Products containing palivizumab for the prevention of RSV infections are classified in J6H9.	
	Also includes inhalation forms of ribavirin where no indication has been specified.	
J5B6	Coronavirus antivirals	I2022
	Includes products containing bamlanivimab, casirivimab, etesevimab, favipiravir, imdevimab, molnupiravir, sotrovimab, regdanvimab, remdesivir, etc, for treatment of COVID-19.	
	Products containing favipiravir for influenza only are classified in J5B4 (influenza antivirals). Products containing favipiravir for both influenza and COVID-19 are classified here.	
	Products containing baricitinib, levilimab, tocilizumab, etc (immunosuppressants that have been used in COVID-19) are classified in L4. Dexamethasone (has been used in COVID-19) is also classified elsewhere in the appropriate hormone class.	
	Vaccines for coronavirus are classified in J7E6.	

J5B9	Antivirals, others Includes products containing lysozyme for viral infections.	I2008
------	--	-------

J6E	POLYVALENT IMMUNO-GLOBULINS - INTRAMUSCULAR	R2006
	The action of these homologous substances is based on a wide spectrum of antibodies mainly belonging to the IgG fraction. Includes subcutaneous as well as intramuscular forms.	
J6F	POLYVALENT IMMUNOGLOBULINS - COMBINATION MODULATION - MAINLY INTRAMUSCULAR	
	These homologous immunoglobulins include: - those whose action is not exclusively based on the IgG fraction. - those which exist in combination with other substances. - those which cause a modulation of the immune response.	
J6G	SPECIFIC IMMUNOGLOBULINS - ANTIBACTERIAL	r2022
	These homologous substances (given intramuscularly or intravenously) have a certain antibody titre against a certain specified antigen. Products for post-exposure prophylaxis are classified here. Products for both post-exposure prophylaxis and for treatment are classified here.	
J6G1	Tetanus immunoglobulin	
J6G2	Pertussis immunoglobulin	
J6G9	Other antibacterial immunoglobulins	
	This group includes diphtheria, streptococci, staphylococci and pseudomonas immunoglobulins.	
J6H	SPECIFIC IMMUNOGLOBULINS - ANTIVIRAL	r2022
	These homologous substances (given intramuscularly or intravenously) have a certain antibody titre against a certain specified antigen. Products for post-exposure prophylaxis are classified here. Products for both post-exposure prophylaxis and for treatment are classified here. Monoclonal antibodies for treatment of COVID-19 are classified in J5B6.	
J6H1	Mumps immunoglobulin	
J6H2	Measles immunoglobulin	
J6H3	Rubella immunoglobulin	
J6H4	Hepatitis immunoglobulin	
J6H5	Rabies immunoglobulin	
J6H9	Other antiviral immunoglobulins	r2022
	This group includes varicella-zoster, tick-borne meningo-encephalitis, poliomyelitis, cytomegaly and herpes immunoglobulins. Products containing	

palivizumab for the prevention of RSV infections are classified here.	
---	--

L1G	MONOCLONAL ANTIBODY ANTINEOPLASTICS Antineoplastic monoclonal antibodies against protein kinases are classified here and not in L1H.	R2019
L1G1	Monoclonal antibody antineoplastics, CD20 Includes products containing obinutuzumab, ofatumumab, rituximab, rituximab with hyaluronidase, etc. Products containing ofatumumab for multiple sclerosis only are classified in N7A.	r2022
L1G2	Monoclonal antibody antineoplastics, VEGF/VEGFR Includes products containing bevacizumab, ramucirumab, etc.	I2019
L1G3	Monoclonal antibody antineoplastics, HER-2 Includes products containing margetuximab, pertuzumab, trastuzumab, trastuzumab deruxtecan, trastuzumab emtansine, etc.	r2021
L1G4	Monoclonal antibody antineoplastics, EGFR Includes products containing cetuximab, necitumumab, nimotuzumab, panitumumab, etc.	I2019
L1G5	Monoclonal antibody antineoplastics, PD-1/PD-L1 Includes products containing atezolizumab, avelumab, cemiplimab, durvalumab, nivolumab, pembrolizumab, tislelizumab, etc.	I2019

L1H5	<p>Protein kinase inhibitor antineoplastics, CDK 4/6</p> <p>Includes products containing abemaciclib, palbociclib, ribociclib, etc. Products containing both ribociclib and letrozole are classified here.</p>	I2019
L1H6	<p>Protein kinase inhibitor antineoplastics, BTK</p> <p>Includes products containing acalabrutinib, ibrutinib, tirabrutinib, zanubrutinib, etc.</p>	I2021
L1H9	<p>Protein kinase inhibitor antineoplastics, other</p> <p>Includes all other protein kinase inhibitor antineoplastics, for example those inhibiting HER-2, JAK 1-2, Pi3K, etc.</p> <p>Includes axitinib, cabozantinib, erdafitinib, everolimus, idelalisib, lapatinib, lenvatinib, midostaurin, neratinib, nintedanib, pazopanib, regorafenib, rivoceranib (apatinib), ruxolitinib, sorafenib, sunitinib, temsirolimus, tivozanib, vandetanib, etc.</p> <p>Products containing nintedanib for idiopathic pulmonary fibrosis only are classified in R7D. Products containing nintedanib for cancer only are classified here. Products containing nintedanib for both cancer and idiopathic pulmonary fibrosis are classified in R7D.</p>	r2022
L1J	<p>PROTEASOME INHIBITOR ANTINEOPLASTICS</p> <p>Includes products containing proteasome inhibitors for neoplasms, eg bortezomib, carfilzomib, ixazomib, etc.</p>	I2018
L1K	<p>LIDOMIDE ANTINEOPLASTICS</p> <p>Includes products containing lenalidomide, pomalidomide or thalidomide for multiple myeloma and other cancers.</p> <p>Products containing thalidomide for both cancer and erythema nodosum leprosum (ENL) are classified here. Products containing thalidomide for ENL only are classified in L4X.</p>	I2022
L1L	<p>PARP INHIBITOR ANTINEOPLASTICS</p> <p>Includes products containing niraparib, olaparib, rucaparib, talazoparib, veliparib, etc.</p>	I2022
L1X	<p>ALL OTHER ANTINEOPLASTICS</p>	R2018
L1X1	<p>Alternative preparations for cancer therapy</p> <p>Includes products derived from Viscum (mistletoe).</p>	r2018

L1X2

Out of use

D2022

L1X3	<p>HDAC inhibitor antineoplastics</p> <p>Includes products containing HDAC inhibitors for neoplasms, eg belinostat, entinostat, panobinostat, romidepsin, tucidinostat, vorinostat, etc.</p>	I2018
L1X4	Out of use	D2022
L1X5	<p>CAR T-cell therapy antineoplastics</p> <p>Includes products containing axicabtagene ciloleucel, tisagenlecleucel, etc.</p>	I2019
L1X6	<p>Hedgehog pathway inhibitor antineoplastics</p> <p>Includes products containing glasdegib, sonidegib, vismodegib, etc.</p>	I2022
L1X8	<p>Photosensitisers for cancer therapy</p> <p>Includes products containing photosensitisers for use in cancer therapy, eg aminolaevulinic acid, methyl aminolaevulinate, methoxsalen, porfimer, talaporfin, temoporfin, etc.</p> <p>Products containing aminolaevulinic acid for actinic keratosis, basal cell carcinoma or Bowen syndrome are classified here. Products containing aminolaevulinic acid for use in diagnostic procedures are classified in T1X.</p> <p>Products containing methoxsalen for other skin conditions such as psoriasis or vitiligo are classified in the appropriate D classes.</p> <p>Products containing vertoporphin for macular degeneration are classified in S1P.</p>	r2019
L1X9	<p>All other antineoplastics</p> <p>Includes amsacrine, enzymes, estramustine, gallium nitrate, methylhydralazine, mitotane, procarbazine, substituted urea, tasonermin, vosaroxin. Also includes celecoxib for familial adenomatous polyposis (FAP).</p> <p>Products containing aflibercept for cancer are classified here. Products containing aflibercept for macular degeneration are classified in S1P.</p> <p>Products containing BCG vaccine for cancer are classified here; those for general immunostimulation are classified in L3A9. Products containing BCG vaccine for active immunisation against tuberculosis are classified in J7D6.</p>	r2022

L2	CYTOSTATIC HORMONE THERAPY	I1994
	Includes all types of hormones used primarily in the treatment of cancers, eg adrenocorticoids, progestogens, oestrogens, anti-oestrogens and androgens.	
L2A	CYTOSTATIC HORMONES	I1994
L2A1	Cytostatic oestrogens	I1994
L2A2	Cytostatic progestogens	I1994
L2A3	Cytostatic gonadotrophin-releasing hormone analogues	r2020
	Buserelin, deslorelin, goserelin, nafarelin, leuprorelin and triptorelin are classified here. When these substances are not used as cytostatics they are classified in H1C. Products containing gonadotrophin-releasing hormone analogues for cancer and also for other conditions are classified here.	
L2A9	Other cytostatic hormones	I1994
	Includes substances such as drostanolone, testolactone.	
L2B	CYTOSTATIC HORMONE ANTAGONISTS	I1994
L2B1	Cytostatic anti-oestrogens	R1997
	Includes substances such as tamoxifen, mepitiostane, epitiostanol, toremifene.	
L2B2	Cytostatic anti-androgens	I1994
	Includes substances such as flutamide, nilutamide. Cyproterone acetate (50 mg; injectable forms) is classified here.	
L2B3	Cytostatic aromatase inhibitors	r2019
	Includes aminoglutethamide, anastrozole, exemestane, formestane, letrozole.	
	Products containing both ribociclib and letrozole are classified in L1H5.	
L2B9	Other cytostatic hormone antagonists	r2022
	Includes fulvestrant. Products containing relugolix for cancer are classified here. Products containing relugolix (single ingredient) for uterine fibroids or endometriosis are classified in H1C3. Products containing relugolix in combination with oestrogens and progestogens for uterine fibroids are classified in G3X.	

L4X	<p data-bbox="316 127 834 161">OTHER IMMUNOSUPPRESSANTS</p> <p data-bbox="316 203 1393 275">Immunosuppressants used in the treatment of rejection in organ transplants are classified here, or in L4C if they contain interleukin inhibitors.</p> <p data-bbox="316 315 1393 495">Includes eg antilymphocyte and antithymocyte immunoglobulins, azathioprine, cyclosporin, muromonab-cd3, mycophenolate mofetil, tacrolimus – unless classified elsewhere because of a specific indication or formulation. For example, ophthalmic cyclosporin for dry eye is classified in S1K9 and dermatological tacrolimus is classified in D5X.</p> <p data-bbox="316 535 1393 640">Products for multiple sclerosis are classified in N7A. Products containing natalizumab and indicated for multiple sclerosis and other conditions are classified in N7A.</p> <p data-bbox="316 680 1393 786">Products containing apremilast for psoriatic skin conditions only, are classified in D5B. Psoriatic arthritis is defined as a skin condition. Products containing apremilast for multiple conditions are classified here.</p> <p data-bbox="316 826 1393 1005">Products containing lenalidomide, pomalidomide or thalidomide for multiple myeloma and other cancers are classified in L1K. Products containing thalidomide for both cancer and erythema nodosum leprosum (ENL) are classified in L1K. Products containing thalidomide for erythema nodosum leprosum only are classified here.</p> <p data-bbox="316 1046 1393 1151">Products containing baricitinib, tofacitinib or upadacitinib (JAK inhibitors) for multiple conditions are classified here. Products containing baricitinib, tofacitinib or upadacitinib for rheumatoid arthritis only are classified in M1C.</p> <p data-bbox="316 1191 1393 1296">Products containing leflunomide for multiple conditions are classified here. Products containing leflunomide for rheumatoid arthritis only are classified in M1C.</p> <p data-bbox="316 1337 812 1370">Corticosteroids are not classified here.</p>	r2022
------------	--	-------

M1C	<p data-bbox="316 127 912 161">SPECIFIC ANTI-RHEUMATIC AGENTS</p> <p data-bbox="316 203 1393 383">This class includes abatacept, anakinra, tocilizumab, gold preparations, bucillamine, penicillamine and quinolines (eg oxycinchophen). Includes products containing mesalazine, olsalazine, and sulphasalazine if specifically indicated for rheumatic conditions. Products containing aminosalicylates and used for intestinal inflammatory conditions, are classified in A7E1.</p> <p data-bbox="316 425 1393 492">Azathioprine is in L4X. Products containing methotrexate for rheumatic conditions are classified here; otherwise methotrexate is classified in LIB or in D.</p> <p data-bbox="316 535 1129 568">Products containing anti-TNF substances are classified in L4B.</p> <p data-bbox="316 611 1393 716">Products containing baricitinib, tofacitinib or upadacitinib, and indicated for rheumatoid arthritis only, are classified here. Products containing baricitinib, tofacitinib or upadacitinib for multiple conditions are classified in L4X.</p> <p data-bbox="316 759 1393 864">Products containing leflunomide, and indicated for rheumatoid arthritis only, are classified here. Products containing leflunomide for multiple conditions are classified in L4X.</p> <p data-bbox="316 907 1393 1086">Products containing interleukin inhibitors and only indicated for arthritic conditions are classified here, eg anakinra. Products containing tocilizumab and indicated for both arthritis and giant cell arteritis are classified here. Other interleukin inhibitors indicated for multiple conditions including arthritis are classified in L4C.</p> <p data-bbox="316 1128 928 1162">Psoriatic arthritis is defined as a skin condition.</p>	r2022
------------	--	-------

N7	OTHER CNS DRUGS	R1996
N7A	<p>MULTIPLE SCLEROSIS PRODUCTS</p> <p>Products containing alemtuzumab, dimethyl fumarate, fingolimod, glatiramer acetate, laquinimod, teriflunomide, etc, and indicated for multiple sclerosis only, are classified here.</p> <p>Products containing natalizumab and indicated for multiple sclerosis and other conditions are classified here.</p> <p>Products containing alemtuzumab and indicated for cancer only, are classified in L1G9.</p> <p>Products containing daclizumab and indicated for multiple sclerosis and also other conditions are classified here. Products containing daclizumab for use in kidney transplantation only are classified in L4C.</p> <p>Products containing beta interferons and indicated for multiple sclerosis only are classified here. Products containing beta interferons and indicated for both multiple sclerosis and other conditions are classified in L3B2.</p> <p>Products containing mitoxantrone and indicated for both cancer and multiple sclerosis are classified in L1D.</p> <p>Products containing fampridine for improvement in walking in multiple sclerosis are classified in N7X.</p> <p>Products containing ofatumumab for cancer are classified in L1G1.</p> <p>Products containing other substances, eg corticosteroids, immunosuppressants such as azathioprine, that have multiple uses, are classified elsewhere.</p>	r2022
N7B	<p>ANTISMOKING PRODUCTS</p> <p>Includes products used to stop smoking.</p>	
N7C	<p>ANTIVERTIGO PRODUCTS</p> <p>Includes betahistine, cinnarizine and flunarizine when indicated for vertigo and Meniere's disease.</p>	I1996
N7D	ANTI-ALZHEIMER PRODUCTS	I1998
N7D1	Anti-Alzheimer products, cholinesterase inhibitors	R2003
	Includes eg donepezil, galantamine, rivastigmine and tacrine.	
N7D9	All other anti-Alzheimer products	I1998
	Includes all other products specifically used for Alzheimer's disease.	

R3	ANTI-ASTHMA AND COPD PRODUCTS	<u>r2016</u>
	<p>This group includes all preparations indicated for bronchial asthma and chronic obstructive pulmonary disease (COPD). It consists of preparations with bronchodilatory, broncho-spasmodic or anti-asthmatic activity.</p> <p>Bronchodilators combined with expectorants or mucolytics are generally classified in R5C.</p> <p>The need to classify combination products has led to the adoption of a hierarchical system with R3A ingredients taking precedence over R3B etc. Due to the importance of specific combinations, there are some exceptions included in R3C, R3E, R3F, and R3L.</p>	
R3A	B2-AGONISTS	r2016
	<p>This class includes the following substances - bambuterol, bitolterol, carbuterol, clenbuterol, fenoterol, formoterol, isoetarine, isoprenaline, orciprenaline, pirbuterol, procaterol, reproterol, rimiterol, salbutamol, salmeterol, terbutaline, tulobuterol.</p> <p>Excluded are combinations of B2-agonists with non-steroidal respiratory anti-inflammatories (R3E) and combinations of B2-agonists with corticoids (R3F) and combinations of B2-agonists with anticholinergics (with or without corticosteroids) (R3L).</p>	
R3A1	Out of use; can be reused in 2005.	D2002
R3A2	B2-agonists, systemic	r2016
R3A3	Long-acting B2-agonists, inhalant	r2022
	Includes formoterol, salmeterol and procaterol. Includes liquids and capsules to be used as inhalants.	
R3A4	Short-acting B2-agonists, inhalant	r2016
	Includes liquids and capsules to be used as inhalants.	
R3B	XANTHINES	
	This group includes substances such as theophylline, aminophylline, diprophylline etc.	
R3B1	Xanthines, inhalant	
R3B2	Xanthines, systemic	R1993

T2	DIAGNOSTIC TESTS	I1994
T2A	Out of use; can be reused from 2005.	<u>D2002</u>
T2B	Out of use; can be reused from 2005.	D2002
T2C	PREGNANCY AND OVULATION TESTS	I2002
T2D	DIABETES TESTS	I2002
T2D1	Diabetes tests, urine Includes ketone tests.	r2014
T2D2	Diabetes tests, blood Includes ketone tests.	r2014
T2D9	Diabetes tests, other Includes glucose tolerance tests.	I2002
T2X	ALL OTHER DIAGNOSTIC TESTS Includes tests for coronavirus.	r2022
T2X1	All other diagnostic tests, urine	I2002
T2X2	All other diagnostic tests, blood	I2002
T2X9	All other diagnostic tests Includes in vivo and in vitro tests.	I2002

V3G2	<p>Hyperphosphataemia products</p> <p>Includes products used specifically for hyperphosphataemia, eg those containing bixalomer, calcium acetate, calcium acetate in combination with magnesium carbonate, calcium carbonate, colestilan, ferric citrate, lanthanum carbonate, sevelamer, sucroferric oxyhydroxide, etc.</p> <p>Products containing calcium and indicated in both hyperphosphataemia and calcium deficiency are classified in V3G2.</p>	I2016
V3H	<p>ANTI-INFLAMMATORY ENZYMES</p> <p>This group includes all enzyme preparations which are indicated to treat inflammatory conditions. Includes enzyme preparations for respiratory conditions. Excluded are enzyme preparations used in digestive conditions which are classified in A9A. Also excluded are specific cholagogues - classified in A5A, enzymatic topical wound treatments - classified in D3A, enzymes for ophthalmic use - classified in S1S9.</p>	R2007
V3X	<p>ALL OTHER THERAPEUTIC PRODUCTS</p> <p>Includes products with multiple anatomical effects, not readily classifiable in any single group. Large packs of chemicals (bulk packs) which are intended for preparation of formulations in the pharmacy/laboratory are classified here. Kelp products are classified here. Includes medical oxygen cylinders.</p> <p>Products containing omega-3 fatty acids for the reduction of triglycerides and/or the prevention and treatment of arteriosclerosis are classified in C10B. Products containing omega-3 fatty acids for other conditions (including supplementation in pregnancy and breastfeeding) or for multiple uses are classified here.</p> <p>Products containing lonafarnib for Hutchinson-Gilford progeria syndrome or progeroid laminopathies are classified here.</p> <p>4th level used only in Germany and Hungary.</p>	r2022
V3X1	<p>Umstimmungsmittel preparations of herbal origin</p> <p>Products which are said to intensify the body's defence against infection.</p>	I2006
V3X4	<p>Cure-all preparations</p> <p>These products have a broad spectrum of indications for internal and external use. Includes products containing a mixture of homeopathic together with allopathic or herbal ingredients. These products can have several indications.</p>	I2006
V3X5	<p>Homeopathic preparations (1)</p> <p>Includes single homeopathic dilutions named after the homeopathic ingredient (eg belladonna D3) and complex series. These products can have several indications or the indication is not specified.</p>	I2006

